MorphoSys
MorphoSys AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its innovative approach in the field of therapeutic antibodies. Founded in 1992, the company has made significant strides in the development of treatments for cancer and autoimmune diseases, establishing a strong presence in Europe and North America. With a focus on proprietary and partnered drug development, MorphoSys has achieved notable milestones, including the successful launch of its flagship product, Monjuvi (tafasitamab), which targets specific forms of lymphoma. The company’s unique technology platforms, such as its Ylanthus® antibody library, enable the rapid discovery of high-quality therapeutic candidates, positioning MorphoSys as a key player in the biopharmaceutical industry. Through its commitment to advancing healthcare, MorphoSys continues to make impactful contributions to patient care and treatment options.
DitchCarbon Score
How does MorphoSys's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MorphoSys's score of 16 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
MorphoSys's reported carbon emissions
In 2023, MorphoSys reported total carbon emissions of approximately 18,856,470 kg CO2e. This figure includes 101,820 kg CO2e from Scope 1 emissions, 1,340 kg CO2e from market-based Scope 2 emissions, and a significant 18,753,310 kg CO2e from Scope 3 emissions, which encompass various categories such as capital goods (10,204,310 kg CO2e) and business travel (1,833,700 kg CO2e). In 2022, the company's total emissions were about 2,236,960 kg CO2e, with Scope 1 emissions at 103,350 kg CO2e, Scope 2 emissions at 1,060,640 kg CO2e, and Scope 3 emissions at 1,072,960 kg CO2e. Despite these figures, MorphoSys has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets indicates a need for further commitment to sustainability practices within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 103,350 | 000,000 |
| Scope 2 | 1,060,640 | 0,000 |
| Scope 3 | 1,072,960 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MorphoSys is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
